Loading
NASDAQHealthcareBiotechnology
Latest quote
$22.14
−$0.59 · -2.60%
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Previous close
$22.14
−$0.59 · -2.60%
Regular session · ET · Market data may be delayed.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Day range
Current $22.14
52-week range
Current $22.14
Regular session · ET · Market data may be delayed.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Day range
Current $22.14
52-week range
Current $22.14
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 |
|---|---|---|
| Revenue | 1.35M USD | — |
| Cost of goods sold | 804K USD | 313K USD |
| Gross profit | 546K USD | −313K USD |
| Research and development | 54.15M USD | 33.86M USD |
| Selling, general, and administrative | 13.55M USD | 7.38M USD |
| Operating expenses | 67.71M USD | 41.24M USD |
| Interest income | 6.63M USD | 3.44M USD |
| Depreciation and amortization | 804K USD | 313K USD |
| Operating income | −67.16M USD | −41.55M USD |
| Net income | −60.63M USD | −39.8M USD |
Company facts updated Sep 20, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$45.33
104.74% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.58M0.00%2.3T USD0.03%$375.43+0.02%
Vanguard Extended Market ETFVXF594.45K0.00%95.4B USD0.05%$235.11-0.47%
Vanguard Russell 2000 ETFVTWO380.96K0.00%18B USD0.06%$115.16-0.42%
Vanguard Russell 2000 Growth ETFVTWG38.13K0.00%1.7B USD0.06%$264.48-0.62%
Vanguard Russell 2000 Value ETFVTWV13.87K0.00%1.4B USD0.06%$191.06-0.51%
Vanguard Russell 3000 ETFVTHR5.63K0.00%6.4B USD0.06%$336.23-0.05%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOVanguard Russell 2000 Growth ETFVTWGVanguard Russell 2000 Value ETFVTWVVanguard Russell 3000 ETFVTHRAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
